Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 1,489 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 1,489 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $37.53, for a total transaction of $55,882.17. Following the sale, the insider owned 54,645 shares in the company, valued at approximately $2,050,826.85. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.52, for a total transaction of $18,760.00.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Trading Down 0.5%

NASDAQ:AGIO opened at $37.00 on Friday. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a 50-day moving average price of $33.41 and a 200 day moving average price of $32.79. The stock has a market capitalization of $2.21 billion, a P/E ratio of -5.28 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. On average, research analysts predict that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Agios Pharmaceuticals in the second quarter worth $239,582,000. Assenagon Asset Management S.A. lifted its position in Agios Pharmaceuticals by 1,714.6% during the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after purchasing an additional 1,782,457 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at $47,800,000. Parkman Healthcare Partners LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at $24,828,000. Finally, SCS Capital Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $22,743,000.

Analysts Set New Price Targets

Several research firms have recently issued reports on AGIO. JPMorgan Chase & Co. lifted their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. HC Wainwright upped their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Citigroup upped their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Bank of America raised their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.